Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition 07/02/2024
Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma05/06/2023